Search

Author/Creator Winer, E P

1. 369TiPPATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). (23rd October 2018)

Authors:
Loibl, S; Metzger, O; Mandrekar, S J; Mundhenke, C; Seiler, S; Valagussa, P; DeMichele, A; Lim, E; Tripathy, D; Winer, E P; Huang, C; Carey, L; Francis, P; Miller, K D; Goetz, M P; Prat, A; Loi, S; Krop, I; Gianni, L; Ciruelos, E M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 37OSubgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries. (24th November 2019)

Authors:
Iwata, H; Im, S-A; Sohn, J; Jung, K H; Im, Y-H; Lee, K S; Inoue, K; Tamura, K; Wong, A; Emens, L A; Barrios, C H; Adams, S; Schneeweiss, A; Diéras, V; Winer, E P; Chui, S Y; Henschel, V; Rugo, H S; Loi, S; Schmid, P
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (3rd May 2018)

Authors:
Curigliano, G; Burstein, H J; Winer, E P; Gnant, M; Dubsky, P; Loibl, S; Colleoni, M; Regan, M M; Piccart-Gebhart, M; Senn, H -J; Thürlimann, B; André, F; Baselga, J; Bergh, J; Bonnefoi, H; Brucker, S Y; Cardoso, F; Carey, L; Ciruelos, E; Cuzick, J
Journal:
Annals of oncology
Issue:
Volume 29:Number 10(2018)
Page Start:
2153
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. LBA1_PRIMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). (23rd October 2018)

Authors:
Schmid, P; Adams, S; Rugo, H S; Schneeweiss, A; Barrios, C H; Iwata, H; Dieras, V; Hegg, R; Im, S-A; Wright, G S; Henschel, V; Molinero, L; Chui, S Y; Funke, R; Husain, A; Winer, E P; Loi, S; Emens, L A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. (26th November 2018)

Authors:
Adams, S; Schmid, P; Rugo, H S; Winer, E P; Loirat, D; Awada, A; Cescon, D W; Iwata, H; Campone, M; Nanda, R; Hui, R; Curigliano, G; Toppmeyer, D; O'Shaughnessy, J; Loi, S; Paluch-Shimon, S; Tan, A R; Card, D; Zhao, J; Karantza, V
Journal:
Annals of oncology
Issue:
Volume 30:Number 3(2019)
Page Start:
397
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. (26th November 2018)

Authors:
Adams, S; Loi, S; Toppmeyer, D; Cescon, D W; De Laurentiis, M; Nanda, R; Winer, E P; Mukai, H; Tamura, K; Armstrong, A; Liu, M C; Iwata, H; Ryvo, L; Wimberger, P; Rugo, H S; Tan, A R; Jia, L; Ding, Y; Karantza, V; Schmid, P
Journal:
Annals of oncology
Issue:
Volume 30:Number 3(2019)
Page Start:
405
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (25th September 2017)

Authors:
Dubsky, P; Curigliano, G; Burstein, H J; Winer, E P; Gnant, M; Loibl, S; Colleoni, M; Regan, M M; Piccart-Gebhart, M; Senn, H -J; Thürlimann, B; André, F; Baselga, J; Bergh, J; Bonnefoi, H; Brucker, S Y; Cardoso, F; Carey, L; Ciruelos, E; Cuzick, J
Journal:
Annals of oncology
Issue:
Volume 29:Number 1(2018)
Page Start:
281
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (13th August 2019)

Authors:
Hortobagyi, G N; Stemmer, S M; Burris, H A; Yap, Y S; Sonke, G S; Paluch-Shimon, S; Campone, M; Petrakova, K; Blackwell, K L; Winer, E P; Janni, W; Verma, S; Conte, P; Arteaga, C L; Cameron, D A; Mondal, S; Su, F; Miller, M; Elmeliegy, M; Germa, C
Journal:
Annals of oncology
Issue:
Volume 30:Number 11(2019)
Page Start:
1842
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (27th April 2018)

Authors:
Hortobagyi, G N; Stemmer, S M; Burris, H A; Yap, Y S; Sonke, G S; Paluch-Shimon, S; Campone, M; Petrakova, K; Blackwell, K L; Winer, E P; Janni, W; Verma, S; Conte, P; Arteaga, C L; Cameron, D A; Mondal, S; Su, F; Miller, M; Elmeliegy, M; Germa, C
Journal:
Annals of oncology
Issue:
Volume 29:Number 7(2018)
Page Start:
1541
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗